Retina

Daniel H. Chang, MD, shares data on a recent study involving a new violet light-filtering chromophore in a preclinical computer simulation testing and randomized clinical study.

Fellows, residents from around the world show promise for future of retinal research.

Investigators at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine conducting experiments in mouse tissues and human cells found that they may be able improve the success rate for regrowing nerve cells damaged by blinding diseases.

Community involvement, research continue to boost treatment in pediatric population.

Emerging technology may facilitate individualized care, disease management.

The FDA has granted Fast Track designation to MeiraGTx's AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM).

Higher levels of 3 macular pigments minimize risk of age-related disease.

Study evaluates the impact of surgical procedure on visual outcomes in patients.

BIGH3 is an extracellular matrix protein that can act in an autocrine, paracrine manner.

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.

Two teams of researchers from Gyroscope Therapeutics and the University of Pennsylvania are joining forces to explore gene therapy targets for three specific serious eye diseases.

Study results could provide a new preferred treatment paradigm for this population.

Nine pediatric patients with Leber congenital amaurosis show visual improvement in clinical trials.

All syringes used for intravitreal injections have pros and cons. Some recently marketed and forthcoming products are coming closer to meeting “ideal” criteria.

Novel OCT system with AI-based image analysis holds promise.

With several clinical trials underway, ocular therapy is seen as having potential in the treatment of a number of gene-related diseases.

Protocol T Extension Study details methods needed to maintain VA gains over time.

Interim data from a cross-sectional study raise concerns that repeated intravitreal injections of an anti-VEGF agent may be associated with a decline in cognitive health.

Newest advances improving ophthalmologists’ performance in operating room.

Patients with pathogenic variants experience lower VA tied to length of IS/OS junction.

Process eliminates need for expensive in-person examination of patients without DR.

Advances in treatment and surgical techniques have transformed patient care.

Investigators reviewed visual acuity, multi-modal retinal imaging, electroretinography, family history.

Programs use detection and treatment to ease burden of eye disease.

Investigators looked at trends by geographic variation in practice patterns, perceptions toward opioids, and patient population

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

Tamer Mahmoud, MD, PhD, discusses autologous retinal transplant (ART) for macular holes, a procedure he developed, which is providing anatomic hole closure in the vast majority of cases as well as increases in visual acuity.

Josh  Anderson, head of U.S. retina sales and marketing for Alcon, outlines what attendees will learn including product updates, new technologies, and practice management materials for ophthalmologists and their patients during the COVID-19 pandemic.

Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.